MedEx answers any queries you might have regarding Apixaban-2.5 purchase, shipping and payment terms.
Feel free to contact support through inquiry form, MedeEx is fully dedicated towards your needs 24/7.
Apixaban 2,5 mg is an anticoagulant, intended for the treatment of blood clots. At a dose of 5 mg twice a day, Apixaban proved to be efficient for the prevention of heart stroke in people suffering from A-fib. At a dose of 2.5 mg twice a day, it has been demonstrated effectiveness in the treatment of thromboprophylaxis in surgical patients.
Apixaban 2,5 mg is intended for the prevention of severe blood clots from forming because of increased heart rate (A-fib) or after arthroplasty (knee replacement surgery). In the patients with atrial fibrillation, part of the heart does not beat regularly, which may lead to the formation of blood clots and increases your chances for having a stroke. In the US, Apixaban is used for the treatment of certain kinds of blood clots (for example, pulmonary embolus) and to prevent their re-occurrence.
Non-valvular atrial fibrillation significantly increases the risk of stroke. In addition to the control of heart rate, prevention of blood clotting is one of the most important therapeutic goals in patients suffering from NVAF. Anticoagulation therapy is recommended for stroke prevention in patients with NVAF.
Nowadays, Warfarin is the mainstay therapy for stroke prevention in NVAF. This drug has been proven to decrease the risk of stroke in patients suffering from NVAF by more than 60% compared to placebo.
Apixaban 2,5 mg is a good alternative to Warfarin for the primary prevention of stroke in patients suffering from NVAF who are considered to be at a high risk of a thromboembolism. Another alternatives of Warfarin are Dabigatran and Evaroxaban.
The common dosage for the treatment of non-valvular AF is 5 mg orally twice a day. For the patients over the age of 80 who weigh less than 60 kg, or those suffering from kidney failure, the recommended dose is 2.5 mg twice a day.
The common dose for the treatment of deep vein thrombosis or PE (pulmonary embolism) is 10 mg twice a day for the first week and then 5 mg twice a day. After half a year of therapy, the dosage should be decreased to 2.5 mg once a day for prevention of deep vein thrombosis/PE.
When Apixaban is taken to avert the risk of deep vein thrombosis after hip/knee replacement surgery, the recommended dose is 2.5 mg once or twice a day.